Sarcoidosis is a multisystem disease involving most frequently the lung, the eyes, the lymph nodes and the skin. Skin lesions may be disfiguring and impair the quality of life. Thalidomide is a multi-target drug that has been shown to be of benefit in skin sarcoidosis in case reports. The objective is to assess the efficacy and tolerance of thalidomide in skin sarcoidosis.
The study consists in comparing thalidomide to placebo in skin sarcoidosis. Patients with sarcoidosis not necessitating a high-dose corticosteroid regimen, and assessable skin lesions, are eligible. They are randomized and receive either thalidomide or placebo for 3 months. Then they are given Thalidomide for a 3-month open-label period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
THALIDOMIDE
HOPITAL Saint Louis, Service de Dermatologie
Paris, France
Size of target skin lesions at 3 months.
Size of target skin lesions at 3 months.
Time frame: during de study
Physician global assessment at 3 months. Functional assessment of other organs. Side-effects at 3 months.
Physician global assessment at 3 months. Functional assessment of other organs. Side-effects at 3 months.
Time frame: during the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.